Long $MRNA
Nathan Worden's avatar
$18 billion of cash on the balance sheet was a big talking point too.
Dissecting the Markets's avatar
They have so much cash that they can play around with numerous clinical trials.
Modern Growth Investing's avatar
@dissectmarkets yep, i think they can scale to a trillion dollar company, they have a great shot at it!
Ben's avatar
Careful only reading the share repurchase amount and not an actual decrease in the number of shares outstanding. These are year end share counts for 2019, 2020, 2021.

That should read despite spending a few billion to repurchase shares, our stock based compensation has managed to out pace us, thus diluting existing shareholders
Nathan Worden's avatar
@rpinvestments Very interesting point!
Modern Growth Investing's avatar
@nathanworden @rpinvestments I disagree look at the ratio of SBC v/s revenues or gross profit
Ben's avatar
@growthinvesting sorry. But I don’t understand how your chart means that the buybacks are decreasing share count
Joshua Simka's avatar
Any thoughts on their pipeline? Does $MRNA need to prove itself beyond vaccines to grow meaningfully from here?